Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-cholesterol drug treats Alzheimer’s disease in mice

14.10.2004


A drug that jams a key enzyme regulating cholesterol drastically reduces the levels of brain-clogging amyloid plaque in mice engineered to have a human form of the amyloid protein. According to Dora Kovacs and her colleagues, the findings suggest that such inhibiting drugs could be used to treat and prevent Alzheimer’s disease (AD).



CP-113,818 mimics a cholesterol molecule that the enzyme, called "acyl-coenzyme A: cholesterol acyltransferase" (ACAT), converts into a form of cholesterol that the cell stores in droplets. When CP-113,818 is administered, it plugs into the "active site" of ACAT, jamming its operation and preventing the enzyme from processing cholesterol.

Cholesterol is required in the production of the short protein called Aß peptide, the building block for the amyloid plaque that clogs the brain in Alzheimer’s disease, ultimately killing brain cells. In the mouse experiments, the researchers administered CP-113,818 by implanting slow-release biopolymer pellets under the skin of both normal mice and transgenic animals engineered to have the human form of the aberrant protein that leads to Aß peptide. Such transgenic mice develop the hallmark pathology of Alzheimer’s, including brain amyloid plaque and memory deficits.


The researchers found that treatment of the normal mice markedly reduced the levels of the storage form of cholesterol in their brains. And in the transgenic animals, the treatment reduced the accumulation of amyloid plaque by 88%–99% percent and reduced the storage form of cholesterol by 86%. When the researchers tested the treated versus untreated animals, they found a slight improvement in the animals’ ability to learn and remember the location of a submerged platform in a water tank--a standard test of learning and memory.

Cholesterol-lowering statins are now being tested as a means of reducing the risk of Alzheimer’s, said the researchers, although "It remains to be shown that statins can provide significant cognitive benefit for AD patients with normal serum cholesterol."

Although CP-113,818 has not been tested in clinical trials, another ACAT inhibitor, avasimibe, developed by Pfizer, is now in final clinical trials as a treatment for vascular disease and atherosclerosis. That drug is "considered safe for human use, with a good therapeutic window," wrote Kovacs and her colleagues. "Our results suggest that slow-release biopolymer administration of ACAT inhibitors may be considered as a potential strategy for the treatment and prevention of Alzheimer’s disease, alone or in combination with statins," they wrote.

Birgit Hutter-Paier, Henri J. Huttunen, Luigi Puglielli, Christopher B. Eckman, Doo Yeon Kim, Alexander Hofmeister, Robert D. Moir, Sarah B. Domnitz, Matthew P. Frosch, Manfred Windisch, and Dora M. Kovacs: "The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer’s Disease"

Heidi Hardman | EurekAlert!
Further information:
http://www.cell.com

More articles from Life Sciences:

nachricht More genes are active in high-performance maize
19.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht How plants see light
19.01.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>